Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethas...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 23 2024
|
| In: |
Blood advances
Year: 2024, Jahrgang: 8, Heft: 2, Pages: 388-398 |
| ISSN: | 2473-9537 |
| DOI: | 10.1182/bloodadvances.2023010579 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2023010579
|
| Verfasserangaben: | Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z. Orlowski, Sung-Soo Yoon, Saad Z. Usmani, Katja Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J. Blake Bartlett, Robin Carson, and Meletios A. Dimopoulos |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1908281707 | ||
| 003 | DE-627 | ||
| 005 | 20241220171141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241112s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023010579 |2 doi | |
| 035 | |a (DE-627)1908281707 | ||
| 035 | |a (DE-599)KXP1908281707 | ||
| 035 | |a (OCoLC)1475647320 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Spencer, Andrew |e VerfasserIn |0 (DE-588)1348011777 |0 (DE-627)1908282649 |4 aut | |
| 245 | 1 | 0 | |a Daratumumab for patients with myeloma with early or late relapse after initial therapy |b subgroup analysis of CASTOR and POLLUX |c Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z. Orlowski, Sung-Soo Yoon, Saad Z. Usmani, Katja Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J. Blake Bartlett, Robin Carson, and Meletios A. Dimopoulos |
| 264 | 1 | |c January 23 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Vorab veröffentlicht: 4. Dezember 2023 | ||
| 500 | |a Gesehen am 12.11.2024 | ||
| 520 | |a High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but patients who relapse early after initial therapy are considered a functional high-risk group. In the phase 3 CASTOR and POLLUX studies, daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS), regardless of cytogenetic risk, and achieved higher rates of complete response or better (≥CR) and minimal residual disease (MRD) negativity vs that with Vd/Rd alone in relapsed/refractory MM. Post hoc analyses of CASTOR and POLLUX evaluated patient subgroups with 1 prior line of therapy based on timing of progression/relapse (early or late) after initiation of first line of therapy. PFS consistently favored the daratumumab-containing regimens across subgroups using both a 24- and 18-month early-relapse cutoff. In the CASTOR/POLLUX pooled data set, daratumumab reduced the risk of disease progression or death by 65% (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.26-0.48; P < .0001) in the early-relapse (<24 months) subgroup and by 65% (HR, 0.35; 95% CI, 0.26-0.47; P < .0001) in the late-relapse (≥24 months) subgroup. OS also favored the daratumumab-containing regimens in both the early-relapse (HR, 0.62; 95% CI, 0.45-0.86; P = .0036) and late-relapse (HR, 0.67; 95% CI, 0.48-0.93; P = .0183) subgroups in the pooled population using a 24-month cutoff. Rates of ≥CR and MRD negativity (10−5) were higher with daratumumab vs control, regardless of progression/relapse timing. Although daratumumab is unable to fully overcome the adverse prognosis of early relapse, our results support the use of daratumumab for patients with 1 prior line of therapy, including for those who progress/relapse early after initial therapy and are considered to have functional high-risk MM. These trials were registered at www.clinicaltrials.gov as #NCT02136134 (CASTOR) and #NCT02076009 (POLLUX). | ||
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mateos, Maria-Victoria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Suzuki, Kenshi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Levin, Mark-David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sonneveld, Pieter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orlowski, Robert Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yoon, Sung-Soo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Usmani, Saad Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weisel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reece, Donna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ahmadi, Tahamtan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pei, Huiling |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayo, Wendy Garvin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gai, Xue |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carey, Jodi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bartlett, J. Blake |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carson, Robin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d Washington, DC : American Society of Hematology, 2016 |g 8(2024), 2 vom: Jan., Seite 388-398 |h Online-Ressource |w (DE-627)873588312 |w (DE-600)2876449-3 |w (DE-576)48043249X |x 2473-9537 |7 nnas |a Daratumumab for patients with myeloma with early or late relapse after initial therapy subgroup analysis of CASTOR and POLLUX |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:2 |g month:01 |g pages:388-398 |g extent:11 |a Daratumumab for patients with myeloma with early or late relapse after initial therapy subgroup analysis of CASTOR and POLLUX |
| 856 | 4 | 0 | |u https://doi.org/10.1182/bloodadvances.2023010579 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241112 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1908281707 |e 4613320879 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Vorab veröffentlicht: 4. Dezember 2023","Gesehen am 12.11.2024"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"January 23 2024"}],"title":[{"title":"Daratumumab for patients with myeloma with early or late relapse after initial therapy","subtitle":"subgroup analysis of CASTOR and POLLUX","title_sort":"Daratumumab for patients with myeloma with early or late relapse after initial therapy"}],"person":[{"given":"Andrew","role":"aut","family":"Spencer","display":"Spencer, Andrew"},{"role":"aut","given":"Philippe","display":"Moreau, Philippe","family":"Moreau"},{"display":"Mateos, Maria-Victoria","family":"Mateos","role":"aut","given":"Maria-Victoria"},{"role":"aut","given":"Hartmut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"},{"family":"Suzuki","display":"Suzuki, Kenshi","role":"aut","given":"Kenshi"},{"family":"Levin","display":"Levin, Mark-David","role":"aut","given":"Mark-David"},{"given":"Pieter","role":"aut","display":"Sonneveld, Pieter","family":"Sonneveld"},{"role":"aut","given":"Robert Z.","family":"Orlowski","display":"Orlowski, Robert Z."},{"family":"Yoon","display":"Yoon, Sung-Soo","role":"aut","given":"Sung-Soo"},{"display":"Usmani, Saad Z.","family":"Usmani","role":"aut","given":"Saad Z."},{"given":"Katja","role":"aut","family":"Weisel","display":"Weisel, Katja"},{"family":"Reece","display":"Reece, Donna","role":"aut","given":"Donna"},{"role":"aut","given":"Tahamtan","family":"Ahmadi","display":"Ahmadi, Tahamtan"},{"role":"aut","given":"Huiling","display":"Pei, Huiling","family":"Pei"},{"role":"aut","given":"Wendy Garvin","family":"Mayo","display":"Mayo, Wendy Garvin"},{"role":"aut","given":"Xue","display":"Gai, Xue","family":"Gai"},{"given":"Jodi","role":"aut","display":"Carey, Jodi","family":"Carey"},{"family":"Bartlett","display":"Bartlett, J. Blake","role":"aut","given":"J. Blake"},{"given":"Robin","role":"aut","display":"Carson, Robin","family":"Carson"},{"role":"aut","given":"Meletios A.","family":"Dimopoulos","display":"Dimopoulos, Meletios A."}],"relHost":[{"pubHistory":["Vol. 1, iss. 1 (November 2016)-"],"recId":"873588312","name":{"displayForm":["American Society of Hematology"]},"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2876449-3"],"eki":["873588312"],"issn":["2473-9537"]},"disp":"Daratumumab for patients with myeloma with early or late relapse after initial therapy subgroup analysis of CASTOR and POLLUXBlood advances","language":["eng"],"note":["Gesehen am 27.04.21"],"origin":[{"publisherPlace":"Washington, DC","dateIssuedDisp":"[2016]-","publisher":"American Society of Hematology"}],"title":[{"title":"Blood advances","title_sort":"Blood advances"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"issue":"2","text":"8(2024), 2 vom: Jan., Seite 388-398","pages":"388-398","year":"2024","volume":"8","extent":"11"}}],"id":{"doi":["10.1182/bloodadvances.2023010579"],"eki":["1908281707"]},"recId":"1908281707","name":{"displayForm":["Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z. Orlowski, Sung-Soo Yoon, Saad Z. Usmani, Katja Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J. Blake Bartlett, Robin Carson, and Meletios A. Dimopoulos"]},"physDesc":[{"extent":"11 S.","noteIll":"Illustrationen"}]} | ||
| SRT | |a SPENCERANDDARATUMUMA2320 | ||